Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.

Gregory D HuhnAimee WilkinCristina MussiniChristoph D SpinnerJohn JezorwskiMohsine El GhaziErika Van LanduytErkki LathouwersKimberley BrownBryan Baughnull null

Published in: HIV research & clinical practice (2021)

D/C/F/TAF was effective with a high barrier to resistance and bone/renal safety benefits, regardless of demographic or clinical characteristics for treatment-naïve and treatment-experienced, virologically-suppressed adults.

Keyphrases

hiv infected
hiv infected patients
antiretroviral therapy
physical activity
human immunodeficiency virus
randomized controlled trial
double blind
combination therapy
open label
placebo controlled
hiv aids
bone mineral density
men who have sex with men